/PRNewswire/ Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced.
This head-to-head pharmacodynamic study in healthy volunteers examined the ability of both OPVEE and intranasal naloxone to reverse opioid-induced respiratory depression, which is the shallow and slow breathing associated with an opioid overdose In this model, OPVEE 2.7mg reversed respiratory depression to 95% of pre-opioid baseline within 5 minutes; a similar reversal following a 4 […]
/PRNewswire/ Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the.
/PRNewswire/ Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of its authorized generic of Narcan® (naloxone.
/PRNewswire/ Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of its authorized generic of Narcan® (naloxone.